Polymorphisms of xenobiotic-metabolizing enzymes, responsible for individual differences in metabolic activation and detoxification reactions, may profoundly modulate the effects of chemical carcinogens. In 829-835 (1997) 
Introduction
Susceptibility to the hazardous action of result in chromosome instability syndromes chemicals may derive from genetic or characterized by defects of DNA repair or acquired characteristics of the individual. In recombination, increased baseline or the case of genotoxic carcinogens, suscepti-induced chromosome damage, and high bility can be associated with individual dif-cancer incidence-may also increase cancer ferences, e.g., in the efficiency of carcinogen in heterozygotes (1, 2) . Besides such hetmetabolism or in the ability to repair DNA erozygotes, sensitivity to genotoxic carcinolesions induced by the carcinogen. Certain gens could be associated, for example, with recessive genes, which among homozygotes subtle genetic polymorphisms influencing This paper was prepared as background for the Workshop on Susceptibility to Environmental Hazards convened by the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC) held DNA repair processes, although such traits have not yet been found in the human population. On the other hand, studies of individual differences in xenobiotic metabolism have revealed an increasing number of polymorphic enzymes that are involved in the metabolism of carcinogens (3, 4) .
Biotransformation, involving metabolic activation and detoxification, plays a central role in determining the ultimate effects of exposure to chemical carcinogens. Depending on the enzyme, there may be one or several mutant alleles that produce enzyme variants with reduced or increased efficiency in comparison with the wild-type form. In some cases, such as the null genotypes of glutathione S-transferases M 1 (GSTMI) and Ti (GSTTI) , the functional enzyme is completely missing (3) .
Numerous epidemiological studies have indicated an over-representation of some metabolic genotypes or phenotypes in various forms of cancer, suggesting that those individuals are excessively prone to such diseases (3, 4) . With the possible exception of tobacco smoking in, for example, lung cancer associated with the GSTMI and cytochrome P450 (CYP) polymorphisms, epidemiology is not usually able to exactly pinpoint the exposures that are responsible for the findings, as the critical influence of carcinogen-metabolizing enzymes occurs several years before exposure-associated cancer develops.
The question of individual sensitivity to genotoxic carcinogens can also be viewed by studying the involvement of genetic polymorphisms in determining genotoxic response after exposure to specific carcinogens. For this purpose, methods based on genotoxicity assays with human cells, such as cytogenetic techniques, are very useful as they can be applied to any exposures known to produce such alterations. Thus, no specific method development for each new exposing agent is required, and the net effect of complex exposures can be evaluated. Differences between genotypes can be assessed by comparing cytogenetic responses after in vitro exposure or in individuals exposed to the genotoxins of interest in vivo.
The present review will concentrate on the application of cytogenetic biomarkers-chromosomal aberrations (CAs), sister chromatid exchanges (SCEs), micronuclei (MN), and numerical chromosome changes-in studies of individual susceptibility related to polymorphisms of carcinogen-metabolizing enzymes.
Cytogenetic Parameters
The four cytogenetic parameters already mentioned-CAs, SCEs, MN, and numerical chromosome alterations-are all based on microscopic analyses of cell specimens, but each of them measures a different genotoxic phenomenon. In humans, cytogenetic alterations are most often scored from peripheral lymphocytes after they have been stimulated to divide in culture by a mitogen, e.g., phytohemagglutinin (5) .
CAs are structural alterations, breaks and rearrangements, in chromosomes, usually observed in metaphase-blocked cells using conventional microscopy (5 (6) . Recently, a simplified FISH method to score chromosome breakage and alterations of chromosome number, using tandem DNA probes specific for a region in chromosome number 1, was reported (7). Polymerase chain reaction-based methods for the analysis of lymphocyte-specific illegitimate chromosome recombination involving human immunoglobulin or immune receptor loci and considered to depict genetic instability have also been described (8, 9) . In two recent independent reports, increased rates of CAs in peripheral lymphocytes were shown to be associated with later development of cancer (10, 11 (14) . MN can also be scored in exfoliated cells of buccal, nasal, esophageal, bronchial, or urothelial mucosa (15) . The presence of whole chromosomes in MN can be checked by identifying centromeric DNA sequences or kinetochore proteins in the MN (16, 17) . MN analysis appears to be a good in vitro tool to investigate the effects of clastogens and agents (aneuploidogens) that induce numerical abnormalities of chromosomes. In vivo, increased MN frequencies have been associated with exposure to ionizing radiation, aging, and gender (18) . In buccal or nasal mucosa, MN induction has clearly been shown for various ethnic tobacco-chewing habits (15) and exposure to formaldehyde (19) .
The development of FISH techniques has made it possible to detect, in a very simple manner, the copy numbers of any specific human chromosome for which a centromeric DNA probe is available (20) . Both aneuploid and polyploid cells are identified, although hyperdiploids cannot usually be distinguished from polyploids unless probes for more than two chromosomes are used. The tandem FISH assay mentioned above provides information on both structural and numerical chromosomal aberrations (7) . Such analyses have thus far been used as biomarkers in humans only in a few cases, although they can be applied, besides peripheral lymphocytes, to any human tissue available.
Genetic Polymorphisms and Cytogenetic Assays in Vrtro
The involvement of a polymorphism in determining the cytogenetic effects of a specific genotoxin can easily be tested in vitro in cultured cells collected from donors representing different genotypes or phenotypes. A requirement is, of course, that the cells used adequately express the polymorphic condition, i.e., in the case of metabolic genes, the enzyme in question.
In the examples available, peripheral lymphocytes have been used, which are also the most convenient choice, because of easy availability and well-established culture techniques ( Table 1) .
The first example of the utilization of the in vitro approach was the study of Wiencke et al. (21) (44) .
The influence of the GSTMI genotype on smoking-induced chromosome damage was further supported by our recent studies, which show a statistically significant association between the GSTMI-null genotype and elevated CA rates (but not SCE or MN) in lymphocytes of smoking Italian greenhouse workers and controls (47, 48) . The effect particularly concerned chromatid-type aberrations. The pesticide exposure of the greenhouse workers had no significant influence on CAs, SCEs, or MN. No dependence of the cytogenetic biomarkers on GSTTI or NAT2 genotypes was observed, except for a slightly higher baseline SCE level among GSTT1-positive donors in comparison with GSTTI-null individuals; this finding was possibly due to chance, as there were only four GSTTI-null subjects (47) .
The preliminary results of another recent study among Danish bus drivers indicated an increasing gradient of CA frequencies from GSTMI-positivelNAT2 fast acetylator genotype to GSTMI-null/ NA T2 slow acetylator genotype (39) . This finding suggested that these genotypes modulate the genotoxic effects of exposures (diesel exhaust) experienced by the bus drivers in their work. Carstensen (50) .
There are also studies suggesting no influence of GSTMI genotype on cytogenetic damage in human lymphocytes, but these data derive from control cultures established for in vitro studies not designed to reveal differences in baseline rate of cytogenetic damage (21) (22) (23) 28) .
The clear difference in sensitivity to DEB (metabolite of 1,3-butadiene) in vitro in association with the GSTTI genotype (above) has also triggered in vivo cytogenetic studies on a possible genotype effect among 1,3-butadiene production workers. The preliminary results of a European study showed an increase in CA in lymphocytes of GSTTI-null workers in comparison with GSTTI-positive workers (51) . A study in the United States on SCEs in 1,3-butadiene producers, however, failed to show any association with the GSTTI genotype (30) . Due to automated processes, exposure to butadiene in the facilities studied was fairly low. The positive European study suggested that genotype determination may improve the sensitivity of cytogenetic assays in detecting the effects of low-level genotoxic exposures.
The American study did confirm the higher background SCE frequency of GSTTI-null subjects as compared with GSTTI-positive individuals (30) . Wiencke et al. (32) calculated that the DEB sensitivity and the GSTTI genotype were the most important factors influencing baseline SCE frequency, explaining 37 and 27%, respectively, of the variation observed. Smoking, for instance, was found to explain only 6 to 16% of the variation. The genotype effect was independent of smoking and was thought to reflect exposure to internal or ubiquitous external factors dependent on glutathione conjugation (32) . One candidate could be ethylene oxide, a tentative substrate of GSTT1 (26), formed by xenobiotic metabolism from endogenous ethylene. CA count was not significantly elevated in the lymphocytes of the DEB-sensitive subjects (28) . Morimoto and Takeshita (41) observed that ALDH2-deficient habitual alcohol drinkers had higher mean frequency of SCEs in lymphocytes than ALDH2-proficient individuals who consumed alcohol daily. This effect probably reflected the higher acetaldehyde levels found in the peripheral blood of the ALDH2-deficient subjects who also showed an elevated level of acetaldehyde adducts in hemoglobin (52 Studies of cytogenetic biomarkers among exposed humans show that the determination of polymorphisms is becoming an increasingly important aspect that may make the assays more sensitive and more specific in identifying the effect and the sensitive subgroups. At present, it seems that at least GSTM1 and GSTTI genotypes of the donors should be studied on a routine basis when in vivo cytogenetic effects are concerned. Rarer genotypes can be evaluated only in large populations-even the 10 to 20% prevalence of the GSTTI-null genotype among Caucasians may be too low to allow evaluation if the exposure groups are small. Besides good knowledge in genetic toxicology and molecular genetics, expertise in epidemiology is becoming quite useful in planning such exercises, and statistical treatment will not be valid without multivariate analyses in which all of the variables can be duly taken into account.
There will also be much to be learned in risk assessment. Restricted still in most cases to surrogate tissues, such as peripheral lymphocytes, instead of the real targets of carcinogenesis, many things can go wrong in assessing the risk. For instance, the expression or role of the critical metabolizing enzymes may vary in different tissues. From these considerations, one arrives at the ethical issues that are dealt with more thoroughly elsewhere in this issue (53) . It is obvious that the cytogeneticist is faced with ethical questions both in sample collection and when the results of the research are used in risk estimation. It can be gathered from what has been presented above that sound conclusions about the role of genetic polymorphisms in determining genotoxic risks can be achieved only when the complex issue has been studied in depth.
Information obtained from cytogenetic studies of genetic polymorphisms can be used to recognize the genotoxically relevant substrates of the polymorphic enzymes, to identify susceptible genotypes, and to improve the sensitivity of cytogenetic assays both in vitro and in vivo. Such knowledge can be utilized in mechanistic studies and cancer epidemiology. In search for the role of genetic polymorphisms in carcinogenesis, the cytogenetic markers form a link in the chain of evidence which stretches from experimental in vitro work, through analyses of exposed humans, to studies on cancer. Genetic polymorphisms can be followed in all of these steps.
